Barclays: BioMarin Is A Buy, Sees $150/Share

By: via Benzinga
In a report published Friday, Barclays analyst Geoff Meacham initiated coverage of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with an ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.